Prime Medicine wins arbitration with Beam Therapeutics over PM647 development rights

Prime Medicine/PM647

Prime Medicine announced a favorable arbitration award in a dispute with Beam Therapeutics over their 2019 Collaboration and License Agreement. The tribunal ruled that PM647 falls within Prime Medicine's licensed field under the agreement, that Prime did not breach the agreement, and awarded no damages to Beam. This clears the regulatory and IP path for PM647 to advance to human trials.

• Tribunal confirmed PM647 is within Prime Medicine's licensed 'Field' under the 2019 Beam agreement.
• Beam's claims for monetary damages and injunctive relief were denied.
• Removes IP uncertainty and licensing risk, freeing Prime to pursue development and commercialization independently.
• Demonstrates Prime's ability to develop alpha-1 therapies outside Beam's scope.